Table 1 Baseline demographic characteristics of the study population.
From: The impact of renal artery stenting on therapeutic aims
Overall | Indication | CORAL | ||||
|---|---|---|---|---|---|---|
HTN | RF | PO | Included | Excluded | ||
N | 74 | 51 | 29 | 30 | 52 | 22 |
Age, mean (sd), years | 63 (15) | 58 (16) | 69 (10) | 68 (10) | 62 (16) | 59 (17) |
% Male | 47 | 45 | 48 | 43 | 43 | 59 |
Vascular history | ||||||
Any vascular disease, n (%) | 41 (55) | 24 (47) | 21 (72) | 23 (76) | 31 (59) | 10 (45) |
Diabetes, n (%) | 12 (16) | 6 (12) | 6 (21) | 7 (23) | 8 (15) | 4 (18) |
Cerebrovascular disease, n (%) | 16 (22) | 10 (20) | 8 (28) | 9 (30) | 12 (23) | 4 (18) |
Ischaemic Heart Disease, n (%) | 31 (42) | 16 (31) | 17 (59) | 18 (60) | 23 (44) | 8 (36) |
Peripheral Arterial Disease, n (%) | 17 (23) | 12 (24) | 9 (31) | 10 (33) | 14 (27) | 3 (14) |
Blood pressure | ||||||
Systolic blood pressure, mean (sd), mmHg | 187 (30) | 195 (27) | 180 (27) | 178 (28) | 187 (30) | 184 (32) |
Diastolic blood pressure, mean (sd), mmHg | 89 (19) | 94 (20) | 84 (15) | 82 (13) | 89 (21) | 89 (12) |
Antihypertensive medications | ||||||
Prescribed medications, mean (sd) | 3 (1) | 4 (1) | 3 (1) | 3 (1) | 3 (1) | 3 (1) |
Diuretic, n (%) | 32 (43) | 41 (80) | 22 (75) | 30 (100) | 40 (76) | 11 (50) |
Doxazosin, n (%) | 33 (45) | 24 (47) | 14 (48) | 17 (57) | 29 (55) | 7 (31) |
β-blocker, n (%) | 42 (57) | 28 (54) | 15 (52) | 20 (67) | 34 (65) | 12 (54) |
ACE inhibitor, n (%) | 20 (27) | 16 (31) | 3 (10) | 4 (13) | 18 (34) | 6 (27) |
Calcium-channel blocker, n (%) | 42 (57) | 30 (58) | 17 (58) | 19 (63) | 39 (75) | 11 (50) |
Renal function | ||||||
Serum creatinine concn, median (IQR), μmol/L | 159 (193) | 124 (136) | 341 (175) | 252 (182) | 152 (148) | 349 (342) |
Estimated glomerular filtration rate, median (IQR), ml/min/1.73 m2 | 25 (35) | 39 (35) | 14 (10) | 18.5 (15) | 33 (35) | 10 (7) |
